SHERMAN COLE: Open Payments
NPI 1609856699 · LEAWOOD, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$916 in 46 payments from 15 companies in 2025. Trend: 2023 $1,079 · 2024 $952 · 2025 $916
Food & beverage: $916
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $221 |
| Vanda Pharmaceuticals Inc. | 4 | $100 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $98 |
| Janssen Pharmaceuticals, Inc | 1 | $79 |
| Supernus Pharmaceuticals, Inc. | 4 | $78 |
| Neurocrine BioSciences, Inc. | 3 | $69 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Almatica Pharma LLC | 2 | $40 |
| Collegium Pharmaceutical, Inc. | 2 | $35 |
| Lundbeck LLC | 2 | $35 |
Products named: VRAYLAR, CAPLYTA, SPRAVATO, Qelbree, REXULTI, INGREZZA, FANAPT, HETLIOZ.
Industry payments across KS — which companies pay providers there.
